Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1) Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1) News, Nityr Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1) By Holly Archer|2021-05-17T18:52:31+01:00August 5th, 2020|News, Nityr| Read More
Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia News, Nityr Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia By Holly Archer|2021-05-17T18:52:31+01:00May 13th, 2020|News, Nityr| Read More
Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology News, Nityr Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology By Holly Archer|2021-05-17T18:52:31+01:00May 5th, 2020|News, Nityr| Read More
Cycle Pharmaceuticals Launches New Informative Online Meeting Series for Patients With Tyrosinemia Type 1 in the US Cycle Pharmaceuticals Launches New Informative Online Meeting Series for Patients With Tyrosinemia Type 1 in the US News, Resource Cycle Pharmaceuticals Launches New Informative Online Meeting Series for Patients With Tyrosinemia Type 1 in the US By Holly Archer|2021-05-17T18:52:31+01:00April 19th, 2020|News, Resource| Read More
Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics News, Nityr Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics By Holly Archer|2021-05-17T18:52:31+01:00December 18th, 2019|News, Nityr| Read More
Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology News, Nityr Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology By Holly Archer|2022-01-28T15:52:20+00:00October 31st, 2019|News, Nityr| Read More
NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia News, Nityr NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia By Holly Archer|2021-05-17T18:52:31+01:00April 28th, 2019|News, Nityr| Read More
Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA News, Nityr Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA By Holly Archer|2021-05-17T18:52:31+01:00November 19th, 2018|News, Nityr| Read More
Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S. Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S. News, Nityr Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S. By Holly Archer|2021-05-17T18:52:31+01:00November 12th, 2018|News, Nityr| Read More
